Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    MDX-1105
Show Display Options
Rank Status Study
1 Active, not recruiting Multiple Ascending Dose (MDX1105-01)
Condition: Cancer, Multiple Indications
Intervention: Biological: Anti-PDL-1 antibody
2 Withdrawn Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
Condition: Stage III or IV Melanoma
Intervention: Biological: BMS-936559 (Anti-PD-L1)

Indicates status has not been verified in more than two years